upadacitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5346 1310726-60-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • upadacitinib hydrate
  • upadacitinib
  • ABT-494
  • rinvoq
Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.
  • Molecular weight: 380.38
  • Formula: C17H19F3N6O
  • CLOGP: 2.45
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 78.32
  • ALOGS: -3.73
  • ROTB: 4
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class AAK1,ABL2,ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CHEK1,CLK1,CLK2,CLK4,CSF1R,DDR1,DYRK1A,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,ERBB2,FGFR1,FLT3,FYN,GAK,GRK1,GRK2,GSK3A,GSK3B,HASPIN,HIPK2,INSR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K4,MAP4K5,MAPK1,MAPK10,MAPK15,MAPK3,MAPK7,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,NTRK1,NTRK2,NTRK3,NUAK1,PDK1,PDK2,PDK4,PIK3CA,PIK3CD,PIK3CG,PRKAA1,PRKAA2,PRKCD,PRKD1,PRKDC,ROCK1,ROCK2,RPS6KA1,SGK1,SIK2,SIK3,SRC,STK17A,STK33,STK4,SYK,TGFBR1,TNIK,TTK,TYRO3,ULK1,ULK2,YES1 122
kinase-selectivity-class ACVR2B,AURKA,AURKB,AURKC,AXL,BLK,CAMK2D,CDK2,CDK9,CLK2,CLK4,DYRK1A,DYRK1B,DYRK2,EGFR,FLT3,GAK,GSK3B,JAK1,JAK2,JAK3,KDR,MAP3K10,MAP3K21,MAP4K1,MAP4K3,MAPK1,MARK1,MARK2,MARK3,MARK4,NTRK1,PDK1,SGK1,SIK2,SIK3,STK17A,TGFBR1,ULK1 39
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 20.893 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 1
rat-kpuu-brain Rat brain Kpuu 0.010 % High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2020 PMDA AbbVie GK
Aug. 16, 2019 FDA ABBVIE INC
Dec. 16, 2019 EMA AbbVie Deutschland GmbH & Co. KG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy interrupted 4517.83 11.60 1463 44401 48645 90533938
COVID-19 1024.53 11.60 775 45089 168068 90414515
Illness 711.97 11.60 469 45395 81500 90501083
Herpes zoster 415.11 11.60 360 45504 94284 90488299
Intentional dose omission 374.57 11.60 182 45682 17601 90564982
Urinary tract infection 300.30 11.60 547 45317 305085 90277498
Acne 294.09 11.60 182 45682 28325 90554258
Product residue present 254.92 11.60 92 45772 4199 90578384
Therapy cessation 235.58 11.60 174 45690 36187 90546396
Influenza 163.56 11.60 270 45594 138994 90443589
General symptom 149.61 11.60 93 45771 14575 90568008
Rash vesicular 145.42 11.60 99 45765 18098 90564485
Surgery 141.12 11.60 142 45722 44745 90537838
Subcutaneous drug absorption impaired 138.45 11.60 86 45778 13459 90569124
Pustular psoriasis 125.14 11.60 91 45773 18465 90564118
Drug ineffective 121.28 11.60 1147 44717 1383151 89199432
Knee arthroplasty 116.64 11.60 175 45689 83007 90499576
Infection 109.73 11.60 417 45447 361677 90220906
Myositis 108.10 11.60 93 45771 24035 90558548
Toxicity to various agents 101.45 11.60 13 45851 287833 90294750
Sinusitis 95.71 11.60 385 45479 342703 90239880
Back disorder 95.44 11.60 89 45775 25542 90557041
Hypotension 89.06 11.60 27 45837 325370 90257213
Ostomy bag placement 87.98 11.60 14 45850 5 90582578
Drug interaction 87.24 11.60 17 45847 276436 90306147
Dermatitis atopic 86.43 11.60 81 45783 23391 90559192
Ileostomy 83.76 11.60 33 45831 1921 90580662
Blood folate decreased 77.94 11.60 30 45834 1640 90580943
Ophthalmic herpes zoster 75.62 11.60 34 45830 2754 90579829
Contraindicated product administered 73.56 11.60 35 45829 320104 90262479
Nasopharyngitis 72.50 11.60 401 45463 406703 90175880
Perineal rash 71.84 11.60 15 45849 76 90582507
Fatigue 71.66 11.60 321 45543 1153702 89428881
Spinal operation 71.02 11.60 51 45813 10145 90572438
Exposure during pregnancy 70.45 11.60 17 45847 238393 90344190
Eczema 69.53 11.60 108 45756 52762 90529821
Bronchitis 69.36 11.60 202 45662 152725 90429858
Lumbosacral plexopathy 68.74 11.60 15 45849 97 90582486
Antibiotic therapy 67.31 11.60 25 45839 1238 90581345
Thrombosis 65.31 11.60 126 45738 73125 90509458
Hospitalisation 64.74 11.60 176 45688 127924 90454659
Eczema herpeticum 63.24 11.60 16 45848 209 90582374
Colostomy 62.68 11.60 24 45840 1293 90581290
Breast cancer female 61.90 11.60 55 45809 14831 90567752
Completed suicide 60.87 11.60 3 45861 145055 90437528
Basal cell carcinoma 59.78 11.60 79 45785 33310 90549273
Febrile neutropenia 58.64 11.60 6 45858 158343 90424240
Herpes zoster cutaneous disseminated 58.39 11.60 15 45849 209 90582374
Disease progression 57.83 11.60 6 45858 156609 90425974
Breast cancer stage II 57.79 11.60 80 45784 35254 90547329
Pulmonary embolism 56.64 11.60 170 45694 130650 90451933
Stoma creation 54.29 11.60 13 45851 133 90582450
Knee operation 53.67 11.60 37 45827 6899 90575684
Oral herpes 52.00 11.60 74 45790 33450 90549133
Disability 51.86 11.60 82 45782 40663 90541920
Asthenia 49.81 11.60 124 45740 533627 90048956
Pneumocystis jirovecii pneumonia 48.05 11.60 57 45807 21559 90561024
Thrombocytopenia 47.64 11.60 23 45841 208702 90373881
Squamous cell carcinoma of skin 46.77 11.60 35 45829 7414 90575169
Acute kidney injury 46.73 11.60 56 45808 320331 90262252
Ileocaecal resection 45.03 11.60 15 45849 537 90582046
Arthralgia 43.89 11.60 593 45271 777929 89804654
Gastrointestinal perforation 42.99 11.60 27 45837 4305 90578278
Faecal calprotectin increased 42.48 11.60 26 45838 3961 90578622
Walking aid user 41.84 11.60 69 45795 35437 90547146
Lipids increased 41.80 11.60 18 45846 1314 90581269
Portosplenomesenteric venous thrombosis 41.80 11.60 7 45857 6 90582577
Hip arthroplasty 40.81 11.60 107 45757 76101 90506482
Cervix carcinoma stage 0 40.43 11.60 14 45850 565 90582018
Insomnia 39.98 11.60 67 45797 333407 90249176
Malignant neoplasm progression 39.69 11.60 4 45860 106866 90475717
Acne cystic 39.68 11.60 15 45849 780 90581803
Embolism venous 39.58 11.60 24 45840 3596 90578987
Nausea 39.42 11.60 366 45498 1109950 89472633
Inflammatory bowel disease 38.64 11.60 27 45837 5144 90577439
SARS-CoV-2 test positive 38.30 11.60 37 45827 11091 90571492
Pharyngitis streptococcal 37.65 11.60 39 45825 12703 90569880
Fracture pain 37.59 11.60 16 45848 1135 90581448
Osteogenesis imperfecta 37.56 11.60 15 45849 905 90581678
Intestinal anastomosis 37.52 11.60 15 45849 907 90581676
Diverticulitis 36.98 11.60 75 45789 45112 90537471
Drug intolerance 35.77 11.60 112 45752 447479 90135104
Somnolence 35.60 11.60 32 45832 209052 90373531
Kidney infection 35.56 11.60 54 45810 25862 90556721
X-ray abnormal 35.53 11.60 74 45790 45350 90537233
Pneumonia 35.49 11.60 485 45379 637574 89945009
Herpes zoster meningitis 35.47 11.60 9 45855 119 90582464
Therapeutic product effect incomplete 35.10 11.60 192 45672 193704 90388879
Infusion related reaction 34.95 11.60 102 45762 416678 90165905
Osteoarthritis 34.89 11.60 193 45671 195537 90387046
Tremor 34.76 11.60 17 45847 153156 90429427
Dislocation of vertebra 34.59 11.60 83 45781 55885 90526698
Dyspnoea 34.50 11.60 283 45581 880672 89701911
Vomiting 34.26 11.60 246 45618 788047 89794536
Pelvic floor muscle weakness 33.66 11.60 8 45856 79 90582504
Intentional overdose 33.61 11.60 4 45860 93830 90488753
Neutropenia 33.11 11.60 39 45825 224865 90357718
Adjustment disorder with depressed mood 32.78 11.60 82 45782 56671 90525912
Overdose 32.17 11.60 20 45844 157689 90424894
Off label use 30.77 11.60 384 45480 1101868 89480715
Spinal cord infection 30.00 11.60 12 45852 727 90581856
Appendicectomy 29.76 11.60 20 45844 3576 90579007
Product use issue 29.69 11.60 78 45786 329841 90252742
Colon cancer 29.68 11.60 32 45832 10912 90571671
Anxiety 29.61 11.60 71 45793 309701 90272882
Mucosal disorder 29.35 11.60 18 45846 2753 90579830
Diverticulitis intestinal perforated 28.87 11.60 10 45854 404 90582179
Respiratory tract infection 28.67 11.60 80 45784 58998 90523585
Neoplasm malignant 28.64 11.60 57 45807 33823 90548760
Colectomy 28.53 11.60 19 45845 3348 90579235
Intentional product use issue 28.44 11.60 41 45823 216851 90365732
Loss of therapeutic response 28.31 11.60 15 45849 1737 90580846
Musculoskeletal pain 28.22 11.60 27 45837 171224 90411359
Retinal detachment 27.95 11.60 25 45839 6797 90575786
Reactive gastropathy 27.87 11.60 11 45853 643 90581940
Intestinal transit time decreased 27.80 11.60 5 45859 9 90582574
Disseminated varicella zoster virus infection 27.75 11.60 10 45854 454 90582129
Gastrectomy 27.69 11.60 12 45852 890 90581693
Herpes ophthalmic 27.62 11.60 14 45850 1480 90581103
Diarrhoea 27.39 11.60 324 45540 938866 89643717
Neuropathy peripheral 27.08 11.60 18 45846 136952 90445631
Constipation 27.01 11.60 64 45800 280331 90302252
Rheumatoid factor 26.75 11.60 10 45854 504 90582079
Colitis 26.67 11.60 87 45777 69855 90512728
Cutaneous T-cell lymphoma 26.55 11.60 14 45850 1606 90580977
Squamous cell carcinoma 26.46 11.60 29 45835 10072 90572511
Depressed level of consciousness 26.32 11.60 3 45861 72781 90509802
Upper respiratory tract infection 25.92 11.60 131 45733 128187 90454396
Thrombocytosis 25.46 11.60 24 45840 6977 90575606
Fluid retention 25.40 11.60 100 45764 87991 90494592
Suicide attempt 25.15 11.60 4 45860 75395 90507188
Balance disorder 24.87 11.60 9 45855 97071 90485512
Bradycardia 24.71 11.60 6 45858 83841 90498742
Dizziness 24.55 11.60 186 45678 589098 89993485
Rotator cuff syndrome 24.48 11.60 35 45829 15884 90566699
Product dose omission in error 24.36 11.60 40 45824 20463 90562120
Nephrolithiasis 24.34 11.60 67 45797 49018 90533565
Breast cancer 24.33 11.60 71 45793 53690 90528893
Abortion induced 24.23 11.60 30 45834 11858 90570725
Small intestinal resection 24.07 11.60 10 45854 668 90581915
Abscess 24.01 11.60 38 45826 18853 90563730
Coma 23.90 11.60 4 45860 72628 90509955
Social problem 23.87 11.60 12 45852 1247 90581336
Agitation 23.69 11.60 3 45861 67095 90515488
Aphthous ulcer 23.68 11.60 36 45828 17251 90565332
Colon operation 23.52 11.60 9 45855 484 90582099
Interstitial lung disease 23.06 11.60 88 45776 76317 90506266
Viral infection 23.04 11.60 59 45805 41355 90541228
Flushing 23.02 11.60 8 45856 88483 90494100
Grip strength decreased 22.70 11.60 100 45764 92476 90490107
Oral lichen planus 22.58 11.60 10 45854 781 90581802
Microstomia 22.33 11.60 5 45859 37 90582546
Coronavirus infection 22.18 11.60 20 45844 5495 90577088
Abdominal discomfort 22.15 11.60 146 45718 477182 90105401
Hidradenitis 22.04 11.60 18 45846 4329 90578254
Psoriasis 22 11.60 139 45725 147615 90434968
Malignant syphilis 21.65 11.60 4 45860 9 90582574
Cervix carcinoma 21.55 11.60 16 45848 3350 90579233
Fractured sacrum 21.30 11.60 14 45850 2413 90580170
Squamous cell carcinoma of the oral cavity 21.13 11.60 8 45856 418 90582165
Death 21.00 11.60 336 45528 456215 90126368
Localised infection 20.98 11.60 50 45814 33512 90549071
Blood glucose increased 20.96 11.60 11 45853 95235 90487348
Immunodeficiency common variable 20.91 11.60 8 45856 430 90582153
Low density lipoprotein increased 20.81 11.60 23 45841 8062 90574521
Cognitive disorder 20.39 11.60 5 45859 69402 90513181
Vulval disorder 20.30 11.60 11 45853 1333 90581250
Myelocytosis 20.18 11.60 6 45858 147 90582436
Anal fistula 20.12 11.60 17 45847 4284 90578299
Hysterectomy 20.10 11.60 27 45837 11557 90571026
Pemphigus 20.09 11.60 91 45773 326773 90255810
Posthaemorrhagic hydrocephalus 20.00 11.60 5 45859 62 90582521
Unevaluable event 19.82 11.60 67 45797 54781 90527802
Hypercholesterolaemia 19.67 11.60 102 45762 100790 90481793
Tooth infection 19.59 11.60 36 45828 20134 90562449
Prostatic specific antigen abnormal 19.58 11.60 5 45859 68 90582515
Respiratory sinus arrhythmia magnitude 19.58 11.60 5 45859 68 90582515
Appendicitis 19.55 11.60 25 45839 10206 90572377
Jejunal stenosis 19.51 11.60 5 45859 69 90582514
Rheumatoid arthritis 19.44 11.60 274 45590 362340 90220243
Ear infection 19.15 11.60 78 45786 69697 90512886
Vulval cancer 19.02 11.60 9 45855 819 90581764
Paternal exposure during pregnancy 19.01 11.60 7 45857 338 90582245
Perioral dermatitis 18.59 11.60 8 45856 583 90582000
Genital herpes zoster 18.45 11.60 4 45860 25 90582558
Malignant melanoma 18.39 11.60 27 45837 12549 90570034
Device loosening 18.38 11.60 9 45855 884 90581699
Intervertebral disc degeneration 18.27 11.60 32 45832 17242 90565341
Neurogenic bladder 18.17 11.60 15 45849 3663 90578920
Gastrointestinal infection 18.14 11.60 25 45839 10965 90571618
Axial spondyloarthritis 18.09 11.60 8 45856 623 90581960
Cutaneous T-cell lymphoma stage IV 18.05 11.60 4 45860 28 90582555
Confusional state 17.97 11.60 118 45746 386087 90196496
Cardiac arrest 17.92 11.60 16 45848 104919 90477664
Gastroenteritis viral 17.67 11.60 44 45820 30311 90552272
Transient ischaemic attack 17.63 11.60 55 45809 43121 90539462
Metatarsalgia 17.56 11.60 7 45857 420 90582163
Blood pressure increased 17.44 11.60 47 45817 197170 90385413
Glossodynia 17.24 11.60 94 45770 321685 90260898
Injection site pain 17.24 11.60 39 45825 173660 90408923
Hepatic cancer metastatic 17.19 11.60 7 45857 444 90582139
Rheumatic disorder 17.04 11.60 14 45850 3394 90579189
Product dose omission issue 16.87 11.60 83 45781 291604 90290979
Syncope 16.49 11.60 26 45838 132637 90449946
Dry mouth 16.17 11.60 44 45820 184015 90398568
Treatment failure 16.17 11.60 89 45775 303839 90278744
Wrong technique in product usage process 16.15 11.60 8 45856 71563 90511020
Hypokalaemia 16.01 11.60 26 45838 131090 90451493
COVID-19 pneumonia 15.87 11.60 31 45833 18146 90564437
Hyponatraemia 15.83 11.60 27 45837 133511 90449072
Pyelonephritis 15.83 11.60 34 45830 21282 90561301
Paraesthesia 15.80 11.60 69 45795 250257 90332326
Hyperhidrosis 15.75 11.60 28 45836 136277 90446306
Postoperative wound infection 15.69 11.60 26 45838 13400 90569183
Gastric cancer 15.68 11.60 16 45848 5120 90577463
Atrial appendage closure 15.62 11.60 4 45860 55 90582528
Skin cancer 15.56 11.60 26 45838 13493 90569090
Anastomotic complication 15.50 11.60 6 45858 333 90582250
Hallucination 15.45 11.60 7 45857 65952 90516631
Feeling abnormal 15.44 11.60 39 45825 167196 90415387
Wound 15.42 11.60 90 45774 302890 90279693
Systemic lupus erythematosus 15.15 11.60 114 45750 361782 90220801
Tibia fracture 15.12 11.60 17 45847 6070 90576513
Sedation 15.10 11.60 3 45861 48168 90534415
Hyperkalaemia 15.06 11.60 7 45857 64957 90517626
Angioedema 15.02 11.60 7 45857 64869 90517714
Fracture 15.02 11.60 34 45830 22042 90560541
Cervical dysplasia 15.00 11.60 14 45850 4020 90578563
Vulval cancer metastatic 14.95 11.60 3 45861 12 90582571
Immunosuppression 14.94 11.60 24 45840 12053 90570530
Intra-abdominal fluid collection 14.89 11.60 12 45852 2832 90579751
Post procedural complication 14.86 11.60 31 45833 19011 90563572
Pleural effusion 14.84 11.60 21 45843 111970 90470613
Intraductal proliferative breast lesion 14.84 11.60 13 45851 3440 90579143
Venous thrombosis limb 14.81 11.60 13 45851 3449 90579134
Urosepsis 14.78 11.60 33 45831 21199 90561384
Cerebrovascular accident 14.70 11.60 110 45754 123423 90459160
Pulmonary fibrosis 14.70 11.60 99 45765 107404 90475179
Cardiac failure congestive 14.64 11.60 17 45847 98677 90483906
Shoulder arthroplasty 14.61 11.60 14 45850 4152 90578431
Shoulder operation 14.59 11.60 12 45852 2914 90579669
Dehydration 14.58 11.60 50 45814 194397 90388186
Vaginal stricture 14.57 11.60 3 45861 14 90582569
Oedema peripheral 14.56 11.60 74 45790 257841 90324742
Metabolic acidosis 14.54 11.60 5 45859 55671 90526912
Hyperglycaemia 14.34 11.60 4 45860 50966 90531617
Skin disorder 14.30 11.60 46 45818 36660 90545923
Anal abscess 14.28 11.60 16 45848 5692 90576891
Angiosarcoma metastatic 14.13 11.60 4 45860 82 90582501
Hypertonic bladder 14.11 11.60 14 45850 4334 90578249
Cystitis 14.09 11.60 69 45795 66649 90515934
Intestinal mucosal atrophy 14.09 11.60 3 45861 17 90582566
Hand deformity 14.06 11.60 90 45774 296272 90286311
Gait inability 13.96 11.60 124 45740 146332 90436251
Laryngeal hypertrophy 13.94 11.60 3 45861 18 90582565
Bone pain 13.88 11.60 7 45857 61976 90520607
Infected lymphocele 13.85 11.60 5 45859 228 90582355
Retinal vein occlusion 13.84 11.60 11 45853 2545 90580038
Atypical mycobacterial lower respiratory tract infection 13.83 11.60 5 45859 229 90582354
Perineal disorder 13.80 11.60 3 45861 19 90582564
Inflammatory marker increased 13.79 11.60 20 45844 9194 90573389
Neck surgery 13.70 11.60 10 45854 2040 90580543
Mucosal inflammation 13.68 11.60 6 45858 57619 90524964
Myelosuppression 13.67 11.60 5 45859 53586 90528997
Oesophageal stenosis 13.66 11.60 13 45851 3823 90578760
Herpes simplex 13.66 11.60 21 45843 10160 90572423
Pseudarthrosis 13.61 11.60 6 45858 464 90582119
Drain placement 13.53 11.60 4 45860 96 90582487
Ankylosing spondylitis 13.47 11.60 24 45840 13109 90569474
Infection susceptibility increased 13.41 11.60 13 45851 3913 90578670
Adverse drug reaction 13.37 11.60 103 45761 116598 90465985
Intervertebral disc protrusion 13.36 11.60 37 45827 27159 90555424
Drug effect less than expected 13.34 11.60 16 45848 6122 90576461
Dysgeusia 13.25 11.60 5 45859 52555 90530028
Colon cancer stage 0 13.19 11.60 3 45861 24 90582559
Chemokine increased 13.19 11.60 3 45861 24 90582559
Rebound eczema 13.18 11.60 8 45856 1200 90581383
Complicated appendicitis 13.15 11.60 4 45860 106 90582477
Fibrin D dimer increased 13.14 11.60 15 45849 5445 90577138
Thoracic vertebral fracture 13.11 11.60 15 45849 5459 90577124
Erythrodermic atopic dermatitis 13.08 11.60 3 45861 25 90582558
Drug specific antibody present 13.02 11.60 15 45849 5499 90577084
Lichen planus 12.99 11.60 11 45853 2780 90579803
Sinusitis aspergillus 12.98 11.60 4 45860 111 90582472
Hiatus hernia 12.95 11.60 35 45829 25326 90557257
Hot flush 12.90 11.60 7 45857 59481 90523102
Lethargy 12.88 11.60 8 45856 63131 90519452
Drug specific antibody absent 12.84 11.60 4 45860 115 90582468
Joint arthroplasty 12.80 11.60 12 45852 3465 90579118
Renal impairment 12.78 11.60 21 45843 105400 90477183
Aphasia 12.74 11.60 3 45861 42809 90539774
Investigation abnormal 12.72 11.60 10 45854 2277 90580306
Osteotomy 12.69 11.60 5 45859 291 90582292
Sepsis 12.67 11.60 143 45721 179671 90402912
Hypertransaminasaemia 12.63 11.60 26 45838 15799 90566784
Gait spastic 12.47 11.60 5 45859 305 90582278
Kidney duplex 12.47 11.60 4 45860 127 90582456
Dysarthria 12.43 11.60 6 45858 54476 90528107
Encephalopathy 12.42 11.60 4 45860 46440 90536143
Bone tuberculosis 12.40 11.60 5 45859 309 90582274
Tympanic membrane perforation 12.31 11.60 10 45854 2387 90580196
Instillation site inflammation 12.25 11.60 3 45861 34 90582549
Spinal stenosis 12.04 11.60 27 45837 17397 90565186
Ileal stenosis 12.02 11.60 10 45854 2468 90580115
Abscess intestinal 11.97 11.60 9 45855 1919 90580664
Fungal infection 11.95 11.60 48 45816 42613 90539970
Malaise 11.87 11.60 384 45480 585602 89996981
Breast prosthesis user 11.86 11.60 4 45860 149 90582434
Respiratory syncytial virus infection 11.85 11.60 20 45844 10460 90572123
Medical device site joint infection 11.68 11.60 5 45859 360 90582223
Acinic cell carcinoma of salivary gland 11.67 11.60 3 45861 42 90582541

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy interrupted 565.79 17.09 233 14854 22017 42584231
Acne 287.00 17.09 125 14962 13519 42592729
Herpes zoster 201.39 17.09 141 14946 38736 42567512
Product residue present 194.66 17.09 62 15025 2779 42603469
Semen discolouration 169.90 17.09 27 15060 25 42606223
Drug ineffective 152.26 17.09 527 14560 629670 41976578
Eczema herpeticum 144.30 17.09 31 15056 277 42605971
COVID-19 142.94 17.09 190 14897 115758 42490490
Illness 142.21 17.09 96 14991 24834 42581414
Faecal calprotectin increased 112.31 17.09 42 15045 3052 42603196
Dermatitis atopic 106.65 17.09 62 15025 12342 42593906
Colectomy 93.32 17.09 34 15053 2295 42603953
Surgery 89.05 17.09 63 15024 17553 42588695
Therapeutic product effect decreased 79.58 17.09 83 15004 39067 42567181
Ileostomy 79.06 17.09 25 15062 1093 42605155
Intentional dose omission 72.21 17.09 43 15044 8943 42597305
Stenosis 70.75 17.09 27 15060 2074 42604174
Embolism venous 69.64 17.09 26 15061 1880 42604368
Ostomy bag placement 66.15 17.09 11 15076 17 42606231
Ileocaecal resection 63.97 17.09 17 15070 397 42605851
Therapeutic product effect incomplete 62.10 17.09 99 14988 70840 42535408
Ileal stenosis 59.12 17.09 23 15064 1861 42604387
Terminal ileitis 57.45 17.09 17 15070 593 42605655
Frequent bowel movements 53.88 17.09 51 15036 21356 42584892
Stoma creation 50.73 17.09 11 15076 103 42606145
Lipids increased 49.70 17.09 18 15069 1194 42605054
Gastrointestinal wall thickening 49.16 17.09 20 15067 1819 42604429
Intestinal anastomosis 48.00 17.09 14 15073 464 42605784
Drug interaction 46.86 17.09 18 15069 266981 42339267
Pulmonary embolism 45.48 17.09 118 14969 119494 42486754
Cutaneous T-cell lymphoma 44.24 17.09 19 15068 1979 42604269
Ophthalmic herpes zoster 43.71 17.09 16 15071 1094 42605154
Eczema 43.64 17.09 57 15030 34029 42572219
Febrile neutropenia 43.17 17.09 7 15080 185696 42420552
Angiolymphoid hyperplasia with eosinophilia 43.13 17.09 10 15077 130 42606118
Hypotension 42.57 17.09 19 15068 257612 42348636
Inflammatory marker increased 40.86 17.09 27 15060 6729 42599519
Colitis ulcerative 38.63 17.09 47 15040 26128 42580120
Myelodysplastic syndrome unclassifiable 38.60 17.09 9 15078 120 42606128
Thymoma benign 38.48 17.09 8 15079 60 42606188
Inflammation 37.85 17.09 53 15034 33794 42572454
Confusional state 37.46 17.09 7 15080 167590 42438658
Squamous cell carcinoma of skin 37.25 17.09 33 15054 12693 42593555
Inflammatory bowel disease 36.73 17.09 20 15067 3509 42602739
Acute kidney injury 36.47 17.09 46 15041 367291 42238957
Seminoma 34.68 17.09 10 15077 318 42605930
Alopecia areata 34.04 17.09 10 15077 340 42605908
Colectomy total 33.81 17.09 10 15077 348 42605900
Ophthalmic herpes simplex 33.17 17.09 10 15077 372 42605876
Diarrhoea haemorrhagic 33.13 17.09 25 15062 7682 42598566
Acne cystic 32.97 17.09 11 15076 571 42605677
Gastrointestinal perforation 32.27 17.09 20 15067 4466 42601782
Arthralgia 31.60 17.09 150 14937 205088 42401160
Large intestinal ulcer 31.44 17.09 16 15071 2447 42603801
Varicella zoster virus infection 30.61 17.09 16 15071 2585 42603663
Disease progression 30.03 17.09 7 15080 143649 42462599
Therapy cessation 29.01 17.09 36 15051 20414 42585834
Pustule 28.73 17.09 12 15075 1167 42605081
Osteoarthritis 28.45 17.09 39 15048 24366 42581882
Cutaneous lymphoma 28.27 17.09 7 15080 122 42606126
Herpes simplex 28.27 17.09 22 15065 7073 42599175
Skin cancer 28.25 17.09 27 15060 11435 42594813
Gastrointestinal disorder 27.74 17.09 55 15032 46598 42559650
Somnolence 27.35 17.09 8 15079 141097 42465151
Anastomotic ulcer 26.70 17.09 9 15078 482 42605766
Large intestine perforation 26.47 17.09 24 15063 9512 42596736
Ileectomy 26.32 17.09 7 15080 164 42606084
Pneumocystis jirovecii pneumonia 26.04 17.09 38 15049 25143 42581105
Large intestinal stenosis 25.78 17.09 13 15074 1950 42604298
Colitis 25.42 17.09 53 15034 46519 42559729
Immunosuppression 24.90 17.09 22 15065 8431 42597817
Colostomy 24.70 17.09 9 15078 607 42605641
Cytomegalovirus colitis 24.29 17.09 16 15071 3965 42602283
Squamous cell carcinoma of lung 24.07 17.09 13 15074 2243 42604005
Fatigue 23.93 17.09 77 15010 435564 42170684
Unevaluable event 23.56 17.09 43 15044 34245 42572003
Herpes ophthalmic 23.50 17.09 9 15078 698 42605550
Retinal detachment 23.36 17.09 19 15068 6506 42599742
Influenza 23.25 17.09 61 15026 62114 42544134
Malignant melanoma 22.89 17.09 22 15065 9378 42596870
Osteonecrosis 22.62 17.09 28 15059 15837 42590411
Lupus-like syndrome 22.53 17.09 14 15073 3140 42603108
Myeloproliferative neoplasm 22.45 17.09 9 15078 788 42605460
Jugular vein thrombosis 22.27 17.09 12 15075 2062 42604186
Synovial cyst 22.22 17.09 13 15074 2616 42603632
Anorectal swelling 22.00 17.09 4 15083 13 42606235
Neutropenia 21.88 17.09 23 15064 199408 42406840
Anamnestic reaction 21.71 17.09 5 15082 63 42606185
Folliculitis 21.64 17.09 17 15070 5541 42600707
Malabsorption 21.57 17.09 13 15074 2760 42603488
Intestinal stenosis 21.44 17.09 13 15074 2791 42603457
Lung neoplasm malignant 21.42 17.09 30 15057 19117 42587131
C-reactive protein increased 21.40 17.09 60 15027 63500 42542748
Abscess intestinal 20.94 17.09 11 15076 1795 42604453
Lymphadenopathy 20.63 17.09 40 15047 33325 42572923
Herpes zoster cutaneous disseminated 20.17 17.09 6 15081 213 42606035
Anastomotic stenosis 20.10 17.09 7 15080 414 42605834
Infection susceptibility increased 19.99 17.09 9 15078 1049 42605199
General symptom 19.89 17.09 9 15078 1062 42605186
Anastomotic fistula 19.79 17.09 5 15082 95 42606153
Fibromyalgia 19.78 17.09 14 15073 3899 42602349
Nasopharyngitis 19.72 17.09 70 15017 83926 42522322
Thrombocytopenia 19.71 17.09 23 15064 190256 42415992
Neuropathy peripheral 19.32 17.09 6 15081 101847 42504401
Myelomalacia 19.01 17.09 5 15082 112 42606136
Basal cell carcinoma 18.87 17.09 31 15056 22702 42583546
Arthritis bacterial 18.75 17.09 16 15071 5852 42600396
Abdominal abscess 18.59 17.09 15 15072 5078 42601170
Coronavirus infection 18.28 17.09 15 15072 5199 42601049
Metastatic malignant melanoma 18.14 17.09 11 15076 2362 42603886
Musculoskeletal stiffness 17.96 17.09 53 15034 57712 42548536
Prostate cancer 17.92 17.09 45 15042 44598 42561650
Cerebrovascular accident 17.92 17.09 75 15012 97085 42509163
Nausea 17.92 17.09 76 15011 396723 42209525
Impetigo 17.80 17.09 9 15078 1357 42604891
Completed suicide 17.74 17.09 6 15081 96459 42509789
Drug effect less than expected 17.67 17.09 13 15074 3844 42602404
Platelet count decreased 17.54 17.09 14 15073 138567 42467681
Neoplasm malignant 17.53 17.09 30 15057 22713 42583535
Joint arthroplasty 17.48 17.09 8 15079 969 42605279
Ulcer 17.27 17.09 25 15062 16416 42589832
Myocardial infarction 17.17 17.09 88 14999 123921 42482327

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy interrupted 5573.83 11.90 1639 44363 48183 110495114
COVID-19 1123.29 11.90 879 45123 244181 110299116
Illness 973.49 11.90 535 45467 81636 110461661
Herpes zoster 561.72 11.90 419 45583 107960 110435337
Intentional dose omission 501.93 11.90 218 45784 19862 110523435
Urinary tract infection 325.31 11.90 527 45475 325755 110217542
Acne 289.56 11.90 178 45824 33342 110509955
Influenza 226.74 11.90 314 45688 168787 110374510
Therapy cessation 207.01 11.90 162 45840 44695 110498602
Eczema herpeticum 171.72 11.90 40 45962 446 110542851
Surgery 160.69 11.90 135 45867 41148 110502149
Toxicity to various agents 154.53 11.90 12 45990 480543 110062754
Dermatitis atopic 150.86 11.90 107 45895 25434 110517863
Sinusitis 140.91 11.90 352 45650 296336 110246961
Drug interaction 134.78 11.90 23 45979 500160 110043137
Infection 131.26 11.90 389 45613 361811 110181486
Product residue present 122.55 11.90 50 45952 3891 110539406
Faecal calprotectin increased 117.70 11.90 57 45945 6662 110536635
Nasopharyngitis 117.62 11.90 396 45606 393965 110149332
Hypotension 117.45 11.90 36 45966 523813 110019484
Ophthalmic herpes zoster 112.20 11.90 45 45957 3350 110539947
Bronchitis 98.45 11.90 208 45794 156824 110386473
Febrile neutropenia 93.61 11.90 11 45991 316756 110226541
Knee arthroplasty 93.60 11.90 125 45877 64823 110478474
Hospitalisation 91.96 11.90 191 45811 142302 110400995
Eczema 90.49 11.90 130 45872 72163 110471134
Ileostomy 87.07 11.90 34 45968 2358 110540939
Antibiotic therapy 80.40 11.90 26 45976 1036 110542261
Basal cell carcinoma 77.64 11.90 95 45907 45175 110498122
Fatigue 76.85 11.90 255 45747 1215703 109327594
Acute kidney injury 76.62 11.90 91 45911 635339 109907958
Pneumocystis jirovecii pneumonia 75.44 11.90 91 45911 42644 110500653
Completed suicide 75.25 11.90 7 45995 242374 110300923
Squamous cell carcinoma of skin 74.77 11.90 60 45942 17143 110526154
Perineal rash 74.61 11.90 15 45987 77 110543220
Blood folate decreased 73.89 11.90 30 45972 2305 110540992
Drug ineffective 72.98 11.90 957 45045 1519583 109023714
Lumbosacral plexopathy 71.67 11.90 15 45987 97 110543200
Therapeutic product effect incomplete 70.42 11.90 229 45773 223576 110319721
Colectomy 70.29 11.90 35 45967 4343 110538954
Herpes zoster cutaneous disseminated 70.27 11.90 20 45982 513 110542784
Pulmonary embolism 69.79 11.90 222 45780 214252 110329045
Spinal operation 69.53 11.90 48 45954 10924 110532373
Disease progression 66.16 11.90 11 45991 244023 110299274
Embolism venous 65.75 11.90 35 45967 4988 110538309
Ileocaecal resection 63.85 11.90 19 45983 572 110542725
Dyspnoea 60.73 11.90 246 45756 1106626 109436671
Stenosis 60.42 11.90 29 45973 3322 110539975
Knee operation 59.88 11.90 37 45965 6985 110536312
Thrombocytopenia 59.07 11.90 36 45966 348849 110194448
Semen discolouration 57.93 11.90 10 45992 17 110543280
Confusional state 57.65 11.90 66 45936 468614 110074683
Osteoarthritis 57.55 11.90 187 45815 182436 110360861
Ostomy bag placement 57.16 11.90 11 45991 43 110543254
Cutaneous T-cell lymphoma 57.14 11.90 28 45974 3356 110539941
Thrombosis 53.68 11.90 131 45871 108531 110434766
Nausea 52.98 11.90 300 45702 1235390 109307907
Oral herpes 52.83 11.90 70 45932 36010 110507287
General symptom 52.09 11.90 37 45965 8809 110534488
Ileal stenosis 52.08 11.90 26 45976 3244 110540053
Malignant neoplasm progression 51.70 11.90 6 45996 174561 110368736
Kidney infection 50.98 11.90 58 45944 25541 110517756
Infusion related reaction 50.98 11.90 50 45952 381112 110162185
Somnolence 49.92 11.90 31 45971 297418 110245879
SARS-CoV-2 test positive 49.26 11.90 47 45955 16888 110526409
Neutropenia 49.12 11.90 50 45952 374570 110168727
Diverticulitis 48.52 11.90 83 45919 53439 110489858
Arthralgia 48.35 11.90 516 45486 779116 109764181
Vomiting 48.27 11.90 205 45797 910470 109632827
Acne cystic 48.02 11.90 17 45985 895 110542402
Rash vesicular 47.12 11.90 43 45959 14609 110528688
Inflammatory bowel disease 46.67 11.90 32 45970 7202 110536095
Diarrhoea haemorrhagic 46.63 11.90 44 45958 15595 110527702
Gastrointestinal perforation 45.79 11.90 32 45970 7424 110535873
Overdose 45.69 11.90 20 45982 233774 110309523
Thymoma benign 44.96 11.90 9 45993 45 110543252
Pharyngitis streptococcal 44.74 11.90 40 45962 13237 110530060
Neuropathy peripheral 44.53 11.90 10 45992 179267 110364030
Bradycardia 44.46 11.90 6 45996 155511 110387786
Asthenia 44.41 11.90 143 45859 688856 109854441
Contraindicated product administered 42.88 11.90 25 45977 248242 110295055
Ear infection 42.70 11.90 86 45916 62646 110480651
Osteogenesis imperfecta 42.66 11.90 15 45987 774 110542523
Retinal detachment 42.56 11.90 36 45966 11064 110532233
Stoma creation 42.54 11.90 11 45991 194 110543103
Immunosuppression 41.92 11.90 44 45958 17715 110525582
Angiolymphoid hyperplasia with eosinophilia 41.45 11.90 10 45992 131 110543166
Gastrointestinal wall thickening 41.20 11.90 23 45979 3600 110539697
Pneumonia 41.05 11.90 550 45452 876164 109667133
Intentional overdose 40.65 11.90 4 45998 132497 110410800
Subcutaneous drug absorption impaired 40.47 11.90 30 45972 7629 110535668
Herpes zoster meningitis 40.04 11.90 11 45991 247 110543050
Respiratory tract infection 39.34 11.90 90 45912 71527 110471770
Upper respiratory tract infection 39.15 11.90 132 45870 131196 110412101
Breast cancer female 38.95 11.90 36 45966 12432 110530865
Coronavirus infection 38.76 11.90 32 45970 9513 110533784
Skin cancer 38.34 11.90 42 45960 17742 110525555
Insomnia 37.94 11.90 57 45945 360533 110182764
Fracture pain 37.19 11.90 15 45987 1133 110542164
Unevaluable event 36.56 11.90 78 45924 59149 110484148
Herpes ophthalmic 36.29 11.90 17 45985 1845 110541452
Large intestinal ulcer 36.03 11.90 25 45977 5736 110537561
Terminal ileitis 34.76 11.90 16 45986 1668 110541629
Portosplenomesenteric venous thrombosis 34.65 11.90 7 45995 37 110543260
Pustular psoriasis 34.44 11.90 35 45967 13570 110529727
Colon cancer 34.01 11.90 38 45964 16405 110526892
Breast cancer 33.93 11.90 59 45943 38483 110504814
Squamous cell carcinoma 33.70 11.90 40 45962 18423 110524874
Herpes simplex 33.59 11.90 37 45965 15727 110527570
Rheumatic disorder 33.39 11.90 20 45982 3571 110539726
Colitis 33.33 11.90 106 45896 102217 110441080
Neoplasm malignant 32.88 11.90 57 45945 37086 110506211
Inflammatory marker increased 32.65 11.90 35 45967 14434 110528863
Coma 32.64 11.90 5 45997 117864 110425433
Diverticulitis intestinal perforated 31.70 11.90 11 45991 546 110542751
Rotator cuff syndrome 31.68 11.90 37 45965 16757 110526540
Hip arthroplasty 31.61 11.90 71 45931 55742 110487555
Tooth infection 30.84 11.90 42 45960 22174 110521123
Agitation 30.84 11.90 5 45997 113046 110430251
Device loosening 30.76 11.90 12 45990 830 110542467
Diarrhoea 30.56 11.90 315 45687 1139190 109404107
Viral infection 30.54 11.90 68 45934 53071 110490226
Gastroenteritis viral 30.40 11.90 50 45952 31176 110512121
Intentional product use issue 30.35 11.90 35 45967 247871 110295426
Exposure during pregnancy 30.14 11.90 16 45986 167408 110375889
Seminoma 29.81 11.90 9 45993 285 110543012
Abscess intestinal 29.68 11.90 18 45984 3286 110540011
Suicide attempt 29.53 11.90 4 45998 103390 110439907
Arthritis 29.51 11.90 143 45859 167443 110375854
Aphthous ulcer 29.40 11.90 40 45962 21096 110522201
Intervertebral disc protrusion 29.22 11.90 46 45956 27652 110515645
Fractured sacrum 28.96 11.90 15 45987 2021 110541276
Anxiety 28.73 11.90 63 45939 345015 110198282
Squamous cell carcinoma of the oral cavity 28.68 11.90 11 45991 727 110542570
Drug effect less than expected 28.60 11.90 24 45978 7296 110536001
Postoperative wound infection 28.54 11.90 34 45968 15719 110527578
Depressed level of consciousness 28.41 11.90 6 45996 112272 110431025
Malignant melanoma 28.23 11.90 35 45967 16856 110526441
Myelodysplastic syndrome unclassifiable 28.13 11.90 7 45995 105 110543192
Pyelonephritis 28.12 11.90 43 45959 25207 110518090
Lactic acidosis 27.96 11.90 3 45999 92808 110450489
Rheumatoid factor 27.69 11.90 10 45992 558 110542739
Tremor 27.63 11.90 26 45976 202206 110341091
Lung neoplasm malignant 27.46 11.90 50 45952 33792 110509505
Large intestinal stenosis 27.46 11.90 18 45984 3762 110539535
Axial spondyloarthritis 26.82 11.90 11 45991 867 110542430
Lipids increased 26.54 11.90 14 45988 1959 110541338
Retinal vein occlusion 26.50 11.90 18 45984 3989 110539308
Hyponatraemia 26.35 11.90 31 45971 217622 110325675
Pustule 26.22 11.90 17 45985 3487 110539810
Wheezing 26.21 11.90 41 45961 255189 110288108
Spondyloarthropathy 26.20 11.90 13 45989 1601 110541696
Product dose omission in error 26.13 11.90 40 45962 23472 110519825
Loss of therapeutic response 26.02 11.90 15 45987 2495 110540802
Hyperkalaemia 25.92 11.90 12 45990 135784 110407513
Arthritis bacterial 25.88 11.90 27 45975 10793 110532504
Shoulder arthroplasty 25.77 11.90 17 45985 3590 110539707
Anal fistula 25.57 11.90 24 45978 8449 110534848
Bone tuberculosis 25.14 11.90 10 45992 728 110542569
Infection susceptibility increased 24.99 11.90 18 45984 4380 110538917
Pseudarthrosis 24.83 11.90 8 45994 315 110542982
Adverse drug reaction 24.62 11.90 98 45904 105461 110437836
Dizziness 24.45 11.90 180 45822 698013 109845284
COVID-19 pneumonia 24.18 11.90 50 45952 37093 110506204
Decreased appetite 23.99 11.90 109 45893 475737 110067560
Ankylosing spondylitis 23.96 11.90 31 45971 15581 110527716
Large intestine perforation 23.94 11.90 32 45970 16597 110526700
Interstitial lung disease 23.89 11.90 118 45884 139216 110404081
Drug reaction with eosinophilia and systemic symptoms 23.86 11.90 3 45999 82092 110461205
Off label use 23.73 11.90 461 45541 1499724 109043573
Vulval cancer 23.53 11.90 9 45993 590 110542707
Encephalopathy 23.47 11.90 3 45999 81052 110462245
Musculoskeletal pain 23.32 11.90 25 45977 182998 110360299
Microstomia 23.18 11.90 5 45997 38 110543259
Abdominal discomfort 23.12 11.90 85 45917 393773 110149524
Impetigo 23.09 11.90 14 45988 2554 110540743
Varicella zoster virus infection 23.08 11.90 20 45982 6348 110536949
Ophthalmic herpes simplex 23.08 11.90 10 45992 904 110542393
Intestinal transit time decreased 22.26 11.90 6 45996 125 110543172
Metabolic acidosis 22.05 11.90 7 45995 99737 110443560
Ankle operation 22.01 11.90 11 45991 1375 110541922
Pemphigus 21.52 11.90 35 45967 214535 110328762
Atlantoaxial subluxation 21.36 11.90 4 45998 13 110543284
Localised infection 21.36 11.90 52 45950 42996 110500301
Anamnestic reaction 21.28 11.90 5 45997 58 110543239
Pelvic floor muscle weakness 21.20 11.90 5 45997 59 110543238
Back disorder 21.04 11.90 34 45968 20888 110522409
Hypoglycaemia 21.04 11.90 11 45991 116093 110427204
Lumbar spinal stenosis 20.92 11.90 19 45983 6414 110536883
Hallucination 20.90 11.90 8 45994 101424 110441873
Posthaemorrhagic hydrocephalus 20.83 11.90 5 45997 64 110543233
Mucosal inflammation 20.80 11.90 7 45995 96134 110447163
Meningitis 20.78 11.90 25 45977 11677 110531620
Hand deformity 20.67 11.90 37 45965 218469 110324828
Hyperglycaemia 20.62 11.90 5 45997 85085 110458212
Fracture 20.59 11.90 37 45965 24751 110518546
Respiratory sinus arrhythmia magnitude 20.55 11.90 5 45997 68 110543229
Constipation 20.49 11.90 78 45924 357708 110185589
Flushing 20.39 11.90 9 45993 104727 110438570
Cataract 20.34 11.90 76 45926 79409 110463888
Hyperhidrosis 20.28 11.90 29 45973 187269 110356028
Cystitis 20.23 11.90 67 45935 65969 110477328
Hypokalaemia 20.00 11.90 28 45974 182420 110360877
Myelocytosis 20.00 11.90 6 45996 186 110543111
Abscess limb 19.96 11.90 21 45981 8476 110534821
Lethargy 19.93 11.90 7 45995 93569 110449728
Oral lichen planus 19.74 11.90 9 45993 918 110542379
Frequent bowel movements 19.74 11.90 70 45932 71320 110471977
Squamous cell carcinoma of lung 19.70 11.90 13 45989 2746 110540551
Intestinal stenosis 19.55 11.90 16 45986 4699 110538598
Eye infection 19.48 11.90 27 45975 14491 110528806
Cytomegalovirus colitis 19.41 11.90 19 45983 7042 110536255
Drug intolerance 19.38 11.90 95 45907 406417 110136880
Metatarsalgia 19.34 11.90 7 45995 393 110542904
Blood glucose increased 19.34 11.90 16 45986 132480 110410817
Appendicitis 19.34 11.90 39 45963 28425 110514872
Lung opacity 19.24 11.90 24 45978 11628 110531669
Nephrolithiasis 19.24 11.90 66 45936 66146 110477151
Kidney duplex 19.23 11.90 4 45998 25 110543272
Laryngeal hypertrophy 19.23 11.90 4 45998 25 110543272
Ileal ulcer 19.21 11.90 11 45991 1806 110541491
Sedation 19.19 11.90 3 45999 69680 110473617
Abortion induced 19.16 11.90 20 45982 7999 110535298
Drain placement 19.06 11.90 6 45996 219 110543078
Glossodynia 18.91 11.90 40 45962 221964 110321333
Cardiac arrest 18.90 11.90 33 45969 196720 110346577
Respiratory distress 18.89 11.90 3 45999 68871 110474426
Anastomotic stenosis 18.84 11.90 8 45994 688 110542609
Transient ischaemic attack 18.79 11.90 64 45938 63918 110479379
Spinal fusion surgery 18.66 11.90 21 45981 9135 110534162
Renal impairment 18.65 11.90 31 45971 188414 110354883
Perioral dermatitis 18.57 11.90 8 45994 713 110542584
Neurogenic bladder 18.51 11.90 16 45986 5063 110538234
Retinal tear 18.35 11.90 11 45991 1966 110541331
Varicella 18.27 11.90 14 45988 3741 110539556
Femur fracture 18.23 11.90 50 45952 44419 110498878
Blood creatinine increased 18.18 11.90 30 45972 182859 110360438
Acute myocardial infarction 18.13 11.90 76 45926 83701 110459596
Venous thrombosis limb 18.01 11.90 16 45986 5249 110538048
Lung adenocarcinoma 17.98 11.90 21 45981 9510 110533787
Multiple organ dysfunction syndrome 17.94 11.90 22 45980 151688 110391609
Abscess 17.91 11.90 37 45965 27432 110515865
Spinal stenosis 17.86 11.90 30 45972 19026 110524271
Wrong technique in product usage process 17.82 11.90 7 45995 87341 110455956
Anal abscess 17.69 11.90 23 45979 11615 110531682
Neck surgery 17.66 11.90 11 45991 2106 110541191
Dermatitis acneiform 17.62 11.90 24 45978 12671 110530626
Therapeutic product effect decreased 17.62 11.90 167 45835 244149 110299148
Limb operation 17.41 11.90 14 45988 4010 110539287
Cerebrovascular accident 17.35 11.90 132 45870 181152 110362145
Gastrointestinal infection 17.25 11.90 25 45977 13980 110529317
Laparotomy 17.23 11.90 7 45995 539 110542758
Tendon rupture 17.15 11.90 25 45977 14053 110529244
Focal peritonitis 17.14 11.90 4 45998 45 110543252
Hepatitis 17.12 11.90 8 45994 90046 110453251
Jejunal stenosis 17.12 11.90 5 45997 141 110543156
Balance disorder 17.11 11.90 14 45988 116546 110426751
Shoulder operation 17.10 11.90 13 45989 3432 110539865
Disseminated varicella zoster virus infection 16.97 11.90 9 45993 1272 110542025
Anastomotic fistula 16.85 11.90 5 45997 149 110543148
Joint arthroplasty 16.80 11.90 13 45989 3524 110539773
Intraductal proliferative breast lesion 16.76 11.90 12 45990 2893 110540404
Plasma cell myeloma 16.69 11.90 3 45999 62933 110480364
Iron deficiency anaemia 16.60 11.90 39 45963 31520 110511777
Spondylitis 16.60 11.90 22 45980 11316 110531981
Intestinal anastomosis 16.53 11.90 8 45994 933 110542364
Vulval cancer metastatic 16.46 11.90 3 45999 8 110543289
Cellulitis 16.39 11.90 99 45903 125917 110417380
Faecal calprotectin abnormal 16.39 11.90 6 45996 348 110542949
Superinfection bacterial 16.39 11.90 11 45991 2390 110540907
Malignant syphilis 16.33 11.90 4 45998 56 110543241
Intervertebral disc degeneration 16.33 11.90 28 45974 18057 110525240
Cutaneous T-cell lymphoma stage IV 16.27 11.90 4 45998 57 110543240
Hepatic cancer metastatic 16.20 11.90 8 45994 975 110542322
Myeloproliferative neoplasm 16.19 11.90 9 45993 1396 110541901
Investigation abnormal 16.16 11.90 11 45991 2445 110540852
Renal failure 16.01 11.90 45 45957 226529 110316768
Cervix carcinoma 15.98 11.90 11 45991 2490 110540807
Haematochezia 15.83 11.90 92 45910 115432 110427865
Atrial appendage closure 15.66 11.90 4 45998 67 110543230
Blood pressure increased 15.66 11.90 55 45947 258318 110284979
Breast neoplasm 15.64 11.90 8 45994 1050 110542247
Myelosuppression 15.58 11.90 10 45992 94330 110448967
Herpes zoster oticus 15.55 11.90 7 45995 693 110542604
Haemoglobin abnormal 15.55 11.90 19 45983 9019 110534278
Angioedema 15.52 11.90 11 45991 98489 110444808
Herpes zoster meningoencephalitis 15.50 11.90 8 45994 1070 110542227
Anastomotic ulcer 15.45 11.90 8 45994 1078 110542219
Mycobacterium tuberculosis complex test positive 15.43 11.90 12 45990 3276 110540021
Cytokine release syndrome 15.42 11.90 5 45997 70301 110472996
Stomatitis 15.41 11.90 59 45943 270183 110273114
Dysgeusia 15.31 11.90 5 45997 69980 110473317
Myelomalacia 15.30 11.90 5 45997 206 110543091
Fat tissue increased 15.29 11.90 8 45994 1100 110542197
Vaginal stricture 15.16 11.90 3 45999 14 110543283
Psoriasis 15.16 11.90 105 45897 139888 110403409
Malaise 15.13 11.90 376 45626 671443 109871854
Small intestinal resection 15.13 11.90 8 45994 1125 110542172
Subcutaneous abscess 15.08 11.90 19 45983 9298 110533999
Cervical dysplasia 15.08 11.90 11 45991 2729 110540568
Feeling abnormal 15.02 11.90 33 45969 180678 110362619
Respiratory arrest 14.99 11.90 3 45999 58296 110485001
Alopecia areata 14.88 11.90 10 45992 2177 110541120
Systemic lupus erythematosus 14.85 11.90 55 45947 254283 110289014
Wound 14.82 11.90 49 45953 234388 110308909
Bone marrow failure 14.82 11.90 3 45999 57845 110485452
Myositis 14.81 11.90 37 45965 31079 110512218
Hypersensitivity 14.68 11.90 103 45899 403895 110139402
Medical device removal 14.65 11.90 7 45995 794 110542503
Proctocolectomy 14.63 11.90 5 45997 237 110543060
Infected lymphocele 14.49 11.90 5 45997 244 110543053
Laparoscopy 14.47 11.90 4 45998 92 110543205
Ectopic pregnancy 14.44 11.90 10 45992 2287 110541010
Meniscus injury 14.42 11.90 17 45985 7776 110535521
Pneumonia bacterial 14.41 11.90 33 45969 26228 110517069
Uterine leiomyoma 14.40 11.90 17 45985 7783 110535514
Rheumatoid arthritis 14.37 11.90 189 45813 299424 110243873
Cholecystectomy 14.35 11.90 20 45982 10789 110532508
Ureterolithiasis 14.31 11.90 13 45989 4389 110538908
Abdominal abscess 14.30 11.90 18 45984 8801 110534496
Fibrin D dimer increased 14.26 11.90 19 45983 9826 110533471
Synovectomy 14.15 11.90 5 45997 262 110543035
Removal of internal fixation 14.13 11.90 3 45999 21 110543276
Hypertonic bladder 14.08 11.90 14 45988 5288 110538009
Gallbladder operation 14.07 11.90 10 45992 2383 110540914
Retinal artery thrombosis 14.04 11.90 4 45998 103 110543194
Deep vein thrombosis 14.03 11.90 103 45899 139784 110403513
Small intestinal stenosis 14.02 11.90 8 45994 1305 110541992
Small intestinal anastomosis 14.00 11.90 3 45999 22 110543275
Transitional cell carcinoma recurrent 14.00 11.90 3 45999 22 110543275
Tachycardia 13.90 11.90 48 45954 226597 110316700
Tongue neoplasm malignant stage unspecified 13.88 11.90 8 45994 1331 110541966
Hysterectomy 13.86 11.90 17 45985 8097 110535200
Loss of consciousness 13.86 11.90 39 45963 196267 110347030
Respiratory syncytial virus infection 13.84 11.90 23 45979 14461 110528836
Neutrophil count decreased 13.82 11.90 18 45984 120923 110422374
Ascites 13.80 11.90 11 45991 92797 110450500
Immune system disorder 13.66 11.90 22 45980 13479 110529818
Intestinal mucosal atrophy 13.56 11.90 3 45999 26 110543271
Malabsorption 13.55 11.90 15 45987 6410 110536887
Atypical mycobacterial lower respiratory tract infection 13.53 11.90 5 45997 298 110542999
Synovial cyst 13.49 11.90 20 45982 11410 110531887
Latent tuberculosis 13.43 11.90 12 45990 3965 110539332
Chemokine increased 13.36 11.90 3 45999 28 110543269
Chondrocalcinosis 13.33 11.90 9 45993 1976 110541321
General physical health deterioration 13.30 11.90 113 45889 425182 110118115
Shock 13.28 11.90 3 45999 53585 110489712
Osteotomy 13.16 11.90 5 45997 322 110542975
Skin infection 13.15 11.90 29 45973 22480 110520817
Perineal fistula 13.09 11.90 4 45998 132 110543165
Colon cancer stage 0 13.09 11.90 3 45999 31 110543266
Instillation site inflammation 13.09 11.90 3 45999 31 110543266
Cardiac failure congestive 13.03 11.90 27 45975 150973 110392324
Heart rate increased 13.03 11.90 25 45977 143809 110399488
Metastatic malignant melanoma 12.95 11.90 11 45991 3398 110539899
Humerus fracture 12.93 11.90 19 45983 10757 110532540
Dehydration 12.92 11.90 66 45936 279445 110263852
Erythrodermic atopic dermatitis 12.92 11.90 3 45999 33 110543264
Oropharyngeal squamous cell carcinoma 12.91 11.90 5 45997 339 110542958
Pleural effusion 12.77 11.90 35 45967 177674 110365623
Mucous stools 12.77 11.90 15 45987 6832 110536465
Medication error 12.76 11.90 15 45987 105351 110437946
Anaemia 12.72 11.90 156 45846 546930 109996367
Erysipelas 12.71 11.90 21 45981 13137 110530160
Gastric infection 12.71 11.90 12 45990 4254 110539043
Anorectal swelling 12.71 11.90 4 45998 146 110543151
Mental status changes 12.67 11.90 8 45994 76114 110467183
Ulcer 12.54 11.90 43 45959 43073 110500224
Immunodeficiency 12.43 11.90 40 45962 38798 110504499
Portal vein thrombosis 12.40 11.90 15 45987 7043 110536254
Pericarditis 12.39 11.90 48 45954 219066 110324231
Infectious mononucleosis 12.34 11.90 9 45993 2233 110541064
Oedema peripheral 12.32 11.90 83 45919 328577 110214720
Full blood count abnormal 12.27 11.90 4 45998 56048 110487249
Cryptitis 12.27 11.90 5 45997 388 110542909
Vitamin C decreased 12.25 11.90 3 45999 42 110543255
Sudden hearing loss 12.24 11.90 9 45993 2260 110541037
Hepatocellular injury 12.22 11.90 3 45999 50639 110492658
Cytomegalovirus enterocolitis 12.20 11.90 9 45993 2272 110541025
Reactive gastropathy 12.12 11.90 6 45996 735 110542562
Acinic cell carcinoma of salivary gland 12.06 11.90 3 45999 45 110543252
Genital herpes zoster 12.06 11.90 3 45999 45 110543252
Swollen tongue 12.04 11.90 5 45997 60357 110482940
Varicella zoster pneumonia 12.02 11.90 5 45997 409 110542888
Accidental exposure to product 12.00 11.90 3 45999 50005 110493292
Foot operation 11.98 11.90 15 45987 7298 110535999
Rectal cancer 11.95 11.90 11 45991 3778 110539519
Neuroendocrine carcinoma of the skin 11.93 11.90 8 45994 1737 110541560

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AF03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Janus-associated kinase (JAK) inhibitors
MeSH PA D000075242 Janus Kinase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018501 Antirheumatic Agents
MeSH PA D047428 Protein Kinase Inhibitors
FDA MoA N0000190857 Janus Kinase Inhibitors
FDA EPC N0000190858 Janus Kinase Inhibitor
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

L04AF Janus-associated kinase (JAK) inhibitors 7 drugs
baricitinibdeucravacitinibdeuruxolitinibfilgotinibpeficitinibritlecitinibtofacitinib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ankylosing spondylitis indication 9631008 DOID:7147
Atopic dermatitis indication 24079001 DOID:3310
Crohn's disease indication 34000006
Ulcerative colitis indication 64766004 DOID:8577
Rheumatoid arthritis indication 69896004 DOID:7148
Psoriatic arthritis indication 156370009 DOID:9008
Nonradiographic axial spondyloarthritis indication 713777005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.85 acidic
pKa2 12.79 acidic
pKa3 3.25 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL 8962629 Jan. 15, 2031 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
1MG/ML RINVOQ LQ ABBVIE N218347 April 26, 2024 RX SOLUTION ORAL 8962629 Jan. 15, 2031 TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
1MG/ML RINVOQ LQ ABBVIE N218347 April 26, 2024 RX SOLUTION ORAL 8962629 Jan. 15, 2031 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 10597400 Oct. 17, 2036 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 10995095 Oct. 17, 2036 TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11365198 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11365198 Oct. 17, 2036 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11512092 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11512092 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11512092 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11512092 Oct. 17, 2036 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11524964 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11535624 Oct. 17, 2036 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11535625 Oct. 17, 2036 TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11767326 Oct. 17, 2036 TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11773106 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11773106 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11773106 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11773106 Oct. 17, 2036 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11780848 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11795175 Oct. 17, 2036 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11976077 Oct. 17, 2036 TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11993605 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11993605 Oct. 17, 2036 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11993606 Oct. 17, 2036 TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 12365689 Oct. 17, 2036 TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 12570664 Oct. 17, 2036 TREATMENT OF ADULTS WITH GIANT CELL ARTERITIS
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 10550126 Oct. 17, 2036 TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 11535626 Oct. 17, 2036 TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 11767326 Oct. 17, 2036 TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
1MG/ML RINVOQ LQ ABBVIE N218347 April 26, 2024 RX SOLUTION ORAL 12365689 Oct. 17, 2036 TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11564922 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11564922 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11607411 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL 11607411 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 11564922 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 11564922 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 11607411 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL 11607411 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL 11564922 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL 11564922 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL 11607411 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL 11607411 March 9, 2038 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL May 18, 2026 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL May 18, 2026 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL May 18, 2026 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL April 26, 2027 NEW PATIENT POPULATION
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL April 26, 2027 TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OF MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL April 26, 2027 NEW PATIENT POPULATION
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL April 26, 2027 TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OF MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL April 26, 2027 NEW PATIENT POPULATION
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL April 26, 2027 TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OF MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS
1MG/ML RINVOQ LQ ABBVIE N218347 April 26, 2024 RX SOLUTION ORAL April 26, 2027 NEW PRODUCT
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL April 28, 2028 TREATMENT OF ADULTS WITH GIANT CELL ARTERITIS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL April 26, 2031 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS, AND FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
30MG RINVOQ ABBVIE N211675 Jan. 14, 2022 RX TABLET, EXTENDED RELEASE ORAL April 26, 2031 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS, AND FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
45MG RINVOQ ABBVIE N211675 March 16, 2022 RX TABLET, EXTENDED RELEASE ORAL April 26, 2031 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS, AND FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
1MG/ML RINVOQ LQ ABBVIE N218347 April 26, 2024 RX SOLUTION ORAL April 26, 2031 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS, AND FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
15MG RINVOQ ABBVIE N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL April 28, 2032 TREATMENT OF ADULTS WITH GIANT CELL ARTERITIS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tyrosine-protein kinase JAK3 Kinase INHIBITOR IC50 5.63 SCIENTIFIC LITERATURE DRUG LABEL
Tyrosine-protein kinase JAK1 Kinase INHIBITOR IC50 7.33 SCIENTIFIC LITERATURE DRUG LABEL
Tyrosine-protein kinase JAK2 Kinase INHIBITOR IC50 6.92 SCIENTIFIC LITERATURE DRUG LABEL
Ribosomal protein S6 kinase alpha-3 Kinase IC50 5.02 CHEMBL
Rho-associated protein kinase 1 Kinase IC50 6.04 CHEMBL
Rho-associated protein kinase 2 Kinase IC50 6.38 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase IC50 5.35 CHEMBL
Fibroblast growth factor receptor 1 Kinase IC50 5.32 CHEMBL
Serine/threonine-protein kinase 16 Kinase IC50 5.01 CHEMBL
Protein kinase C theta type Kinase IC50 5.29 CHEMBL
Aurora kinase A Kinase IC50 5.35 CHEMBL
ALK tyrosine kinase receptor Kinase IC50 5.26 CHEMBL
Tyrosine-protein kinase Lck Kinase IC50 5 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase IC50 5.64 CHEMBL
Activated CDC42 kinase 1 Kinase IC50 5.29 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase INHIBITOR IC50 5.33 IUPHAR
Leukocyte tyrosine kinase receptor Kinase IC50 5.57 CHEMBL
Aurora kinase B Kinase IC50 5.26 CHEMBL
G protein-coupled receptor kinase 5 Kinase IC50 5.10 CHEMBL
Cyclin-G-associated kinase Kinase Kd 5.66 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase IC50 5.62 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 5.82 CHEMBL
Tyrosine-protein kinase JAK3 Kinase IC50 5.73 CHEMBL
Tyrosine-protein kinase JAK2 Kinase IC50 6.23 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase IC50 5.57 CHEMBL

External reference:

IDSource
4RA0KN46E0 UNII
4038662 VANDF
C4726929 UMLSCUI
CHEBI:755661 CHEBI
CHEMBL3622821 ChEMBL_ID
58557659 PUBCHEM_CID
DB15091 DRUGBANK_ID
CHEMBL5315119 ChEMBL_ID
D10994 KEGG_DRUG
10209 INN_ID
C000613732 MESH_SUPPLEMENTAL_RECORD_UI
9246 IUPHAR_LIGAND_ID
789397000 SNOMEDCT_US
789416006 SNOMEDCT_US
321410 MMSL
37314 MMSL
d09350 MMSL
018092 NDDF
2196092 RXNORM
4RA0KN46E0 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-1043 TABLET, EXTENDED RELEASE 45 mg ORAL NDA 34 sections
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-1043 TABLET, EXTENDED RELEASE 45 mg ORAL NDA 34 sections
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-2306 TABLET, EXTENDED RELEASE 15 mg ORAL NDA 34 sections
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-2306 TABLET, EXTENDED RELEASE 15 mg ORAL NDA 34 sections
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-2310 TABLET, EXTENDED RELEASE 30 mg ORAL NDA 34 sections
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-2310 TABLET, EXTENDED RELEASE 30 mg ORAL NDA 34 sections
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-2320 SOLUTION 1 mg ORAL NDA 34 sections
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-2320 SOLUTION 1 mg ORAL NDA 34 sections